Sangamo Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and a Favorable Safety Profile
Design of STEADFAST Study Evaluating TX200-TR101: A Chimeric Antigen Receptor (CAR) T Regulatory Cell Therapy for Living Donor Renal Transplant Recipients